



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Adherence Of Developing Countries To Good Pharmacy Practice: A Systematic Review

Badri K.C.¹, Uttam Budhathoki¹, Naeti Suksumboon², Asta Ratna Prajapati¹, Rojeena Koju Srestha³, Sweta Shrestha¹, Nayan Manandhar³, Achyut Bikram Thapa, Santosh K.C.⁴

Kathmandu University, School of Science, Department of Pharmacy, P.O Box: 6250, Dhulikhel

ARTICLE INFO

Published: 23 Aug. 2026

Keywords:

Good Pharmacy Practice, adherence rate, assessment tool, developing countries, systematic review.

DOI:

10.5281/zenodo.22060676

ABSTRACT

With the development of Good Pharmacy Practice (GPP) guidelines and adherence to it assessed in developing countries, there is necessity for a systematic approach to outline the scenario of GPP practices. Thus, this systematic review aimed to collate the GPP adherence rates of developing countries. A systematic search of PubMed, Google Scholar, CINAHL, Scopus and Embase was conducted for studies published between January 1990 and December 2025. Data were extracted as per the structured rubric, with following headings; year of publication, study country, sample size, data collection tool and validation status, reported adherence rate, and domain-specific GPP adherence score. Seventeen studies out of ninety-one that spanned across nine developing countries were included for review. GPP adherence reported in the articles ranged from 43.2% to 89%. The most commonly explored domains of GPP were storage, service, health promotion facilities, dispensing, and rational use of medicine. The most commonly used tool was self-developed questionnaires. Implementation efforts by concerned stakeholders is necessary to increase adherence rate by identifying barriers to GPP. Additionally, to assure the GPP assessment's reflectability to the real practice and relatability among countries, it is necessary to develop domain specific standardized GPP assessment tool.

INTRODUCTION

“Good Pharmacy Practice (GPP) in community and hospital pharmacy setting” a pharmacy services practice standard developed in 1992, was the first and crucial step of the International

Pharmaceutical Federation (FIP) to help countries achieve standard pharmacy practice [1]. However, a huge gap in pharmacy practice in terms of service orientation and quality assurance existed and still exists between developed and developing countries [2]. In high-income countries Pharmacist

***Corresponding Author:** Uttam Budhathoki

Address: Kathmandu University, School of Science, Department of Pharmacy, P.O Box: 6250, Dhulikhel

Email ✉: uttam@ku.edu.np

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



services are integrated into healthcare teams, focused towards patient care and standard. Whereas, in low and middle-income countries it is still in the process of recognition and integration [3] and the assurance on the quality of pharmacy services seems to lack due to the key challenges like regulatory and governance gaps, infrastructure and resource limitations, human resource constraints, educational and training gaps and systemic and communication barriers [4]. Thus, the FIP developed a separate guidelines for developing countries, “Good Pharmacy Practice in developing countries: Recommendations for stepwise implementation” which was endorsed by the FIP Congress in 1998 in The Hague, recognizing the difference in the level of Pharmacy practice [2].

Since the release of developing countries specific GPP guidelines, countries such as India [5,6], South Africa [7], Sri Lanka [8] and Philippines [9] developed their own guidelines and many others included the key guideline points into governmental rules and regulation [10]. In March 2002, the Indian Pharmaceutical Association developed GPP guidelines focused on Community Pharmacy [6] and later in 2015 India developed GPP regulation [5]. Likewise in 2021, Sri Lanka endorsed GPP guidelines [8]. Accordingly, the Nepal Pharmacy Council drafted the national GPP guideline for Nepal [11] in 2005, which was finally included as a part of the schedule of “The code on sales and distribution of drug” in April 2024 [12] but only for voluntary GPP certification purpose. With the availability of the GPP guidelines GPP assessment has proven crucial to picturize the practice standard of Pharmacy in those countries there is lack of systematic review on adherence rate of developing countries to GPP, the availability of which would add body of knowledge internationally and help concerned

stakeholders to decide on setting goals to implementing GPP.

The GPP practice philosophy outlines four key roles for pharmacists, which may be tailored to serve the needs of individual countries 1: prepare, obtain, store, secure, distribute, administer, dispense, and dispose of medical products; 2) provide effective medication therapy management; 3) maintain and improve professional performance; and 4) contribute to improving the effectiveness of the healthcare system and public health [13]. Each role is supported by the respective functions pharmacists have to fulfil. Most of the GPP assessment tools are based around the above roles but for routine assessment, Trap *et al.* 2010, is the only indicator-based tool available so far but it too lacks patient care component [14].

Although the formation of the SEAR Pharm forum in 2001 and GPP pilot project in five developing countries [2] reflects FIP’s efforts for GPP implementation in South-east Asian countries, delay in development and adoption of the GPP guidelines from member countries informs on the inadequate efforts from concerned stakeholders toward implementation. Good pharmacy practice is an important standard that highlight the quality of pharmacy services [15] and quantifying it is very crucial in understanding the level at which a particular Pharmacy’s practice prevail. For example; One of the first GPP assessment studies in 2007 reported 45.1% adherence rate to GPP which was assessed utilizing Country Checklist [16]. Such understanding can inform Pharmacists and implementation stakeholders to evidence-based decisions regarding milestones and implementation process. This quantification to broader level through systematic review can render far more benefits in understanding the scenario. But there is lack of systematic review of



adherence rates of GPP in developing countries. As the review has reported the tools, questionnaires, and checklists used for GPP assessment and adherence to individual domains, the study can help in improving pharmacy practices and healthcare outcomes in developing countries by informing the current scenario of pharmacy practice standard and gaps in individual domain of GPP. Thus, the aim of this systematic review is to collate the findings from the researches available so far on GPP assessment studies from developing countries.

2. Material and methods

The research protocol based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [17] was registered with International Prospective Register of Systematic Reviews (PROSPERO)(registration number: CRD42024552596)[18].

2.1. Eligibility criteria: The eligibility criteria for this study were guided by the PICOS framework: Participants/population, Interventions, Comparators, Outcomes, and Study design. Studies that did not meet the following inclusion criteria were excluded:

2.2. Participant/population: Community pharmacy, hospital pharmacy or health facility meaning any pharmacy other than community or hospital pharmacy

2.3. Intervention: As the review is related to adherence rate, no intervention criteria was set.

2.4. Comparators: Not applicable

2.5. Outcome measures: Adherence rate to Good Pharmacy Practice

2.6. Study design: Cross-sectional

2.7. Data source, search strategy and screening

A systematic search of PubMed, Google Scholar, CINAHL, Embase and Scopus was conducted for studies published between January 1990 and December 2025 that assessed GPP adherence in developing countries. Additionally, citation and grey literature search from Nepal was done. The duration of study was from June 2024 to December 2025. Only primary quantitative literature in English was considered for review. Correspondence was made to the Head of the Department of Pharmacy of the Universities of Nepal (Kathmandu University, Tribhuvan University, Pokhara University, and Purbanchal University) for the availability of grey literature from Nepal. Zotero 7.0.30 software was used to document a collection of screened articles from the initial run (BKC) and removal of the duplicates.

The search strategies for different databases are as follows:

PubMed: (((compliance [Title/Abstract]) OR (adherence [Title/Abstract])) OR (assessment [Title/Abstract])) AND (good pharmacy practice*[Title/Abstract])

Google scholar: allintitle: good pharmacy practice assessment OR adherence OR compliance

Scopus: (TITLE (good pharmacy practice) AND TITLE (assessment OR adherence OR compliance)) AND PUBYEAR > 1989 AND PUBYEAR < 2026 AND (LIMIT-TO (LANGUAGE, "English"))

Embase: 'good pharmacy practice':ab,ti AND ('adherence':ab,ti OR 'compliance':ab,ti OR 'assessment':ab,ti) AND [1990-2025]/py

CINAHL: XB (good pharmacy practice) AND XB (adherence or assessment or compliance)



The process of identifying, screening, and including or excluding studies is shown in the PRISMA flow diagram (Figure 1).

2.8. Data extraction, quality assessment and analysis

The studies were distributed among eight reviewers (BKC, RKS, SS, UB, ARP, SKC, NM and ABT) and screened for relevance by considering eligibility criteria in the title and abstract and then in the main body of the articles. The data were then extracted as per the structured rubric, which had the following headings: year of publication, study country, sample size, data collection tool and validation status, reported adherence rate, and domain-specific GPP adherence score. As per the Australian government department of foreign affairs list of developing countries, 2022, literatures were tallied and segregated for inclusion [19]. The quality assessment of the studies was conducted by using modified Newcastle-Ottawa Quality Assessment Scale [20]. following rubric by Emanuela Gualdi-Russo and Luciana Zaccagni., 2026 [21]. It was of moderate quality (Score=12.17). To reduce the risk of bias, individual domains of the GPP have been reported. In addition to that, wherever possible, overall GPP adherence was calculated by identifying the available domains and total score wherever available data allowed. A consensus discussion was adopted as a strategy to resolve conflicts between reviewers during screening and data extraction. Initially two reviewers discussed their interpretations and reasoning for scoring, where discrepancies arose in the assessment of individual studies and wherever consensus could not be reached, a third independent reviewer was consulted. For example, during the sub-analysis of adherence to individual domains, there were differences in opinion regarding the services domain, where it was reported together with health

promotion in one study, while with facilities in another. To address this difference in opinion, the third reviewer was consulted, and it was agreed to place it into the facilities domain.

3. Result and discussion

3.1. Search results: Out of total studies (n=91), of which 86 was identified from five databases viz. PubMed, Google Scholar, Embase, CINAHL and Scopus and two from grey literature source and three from citation search, 17 were included for review (n=21).

Pathak et al. 2025 [22] study was conducted in one hospital only so, it was not considered for review. Two grey literatures [23,24] were added from dissertation collection of universities of Nepal. This process is presented in detail in Figure 1 below. Although the filter date was set from January 1, 1990, to December 31, 2025, only two articles (Wijesinghe *et al.*, 2007 and Tiyyagura *et al.*, 2014) were published between 2007 and 2014. All other studies were published from 2016 onwards. Out of 146 developing countries [19] upon the availability of articles that met the inclusion criteria, this review is based on studies from nine countries: India, Lebanon, Nepal, Sri Lanka, Uganda, Thailand, the Philippines, Lao PDR, and Vietnam.

3.2. Characteristics of included studies: The summary characteristics presented in Table. 2 below shows that the studies assessed GPP in community pharmacy (n=15) [15,16,23–36] hospital pharmacy (n=1) [23] and health facility (n=1) [37]. Two studies, in addition to assessing the GPP score, studied the factors affecting the practice to comply with GPP, problems, and obstacles in pharmacy improvement to meet the GPP requirement [33,35]. A study in Uganda [37] was interventional in nature, and the Supervision, Performance Assessment, and Recognition



strategy (SPARS) was tested to observe changes in GPP behaviors of which adherence to the GPP of the baseline study was considered for the review.

3.3. Assessment tools: Self-developed tool was used in six studies [25,26,29–31,34]. While only Sapkota *et al.*, 2024 [34] and Poudel *et al.*, 2026 [26] was validated, except Gyawali *et al.*, 2017[30], all four had reliability assessed. Three studies used Trap B *et al.*, 2010 indicator tool [23,24,36] but none of them re-validated and assessed reliability although translation to Telugu was done in Tiyyagura *et al.*, 2014. Six studies used country-specific checklist [15,16,28,32,33,35]. one of the studies used the tool developed by Badro *et al.*, 2020 [27] while the tool based on the revision of the former tool and incorporation of WHO/FIP GPP guideline was used by Trap *et al.*, 2016 in which the former tool on Supervision, Performance Assessment, and

Recognition Strategy (SPARS) was pre-tested before using it for the study. The tool is different as it consists of GPP indicators categorized into critical, major, and minor domains. Only indicator-based tool developed by Trap *et al.* in 2010 describes indicators and their scoring requirements in detail [14]. More details on the study characteristics can be found in Table 1.

3.4. GPP Adherence rates

The adherence to GPP reported below is based on the results of the included studies without analysis on them as there was variation in assessment tools and setting and under reporting in domains. The adherence to GPP reported in community pharmacy settings in the included studies ranged from as low as 43.20%[24] to as high as 89%[35]. Other adherence rates in community




Figure 1. Prisma Flow diagram

pharmacy are; 45.1%[16], 45.48%[36], 50.84%[31], 53.52%[25], 56.21%[34], 59.3%[30], 60.48%[28], 65.09%[15], 65.71%[32,33] and 84%[27]. Badro *et al.* 2020 considered 75% as the

cut-off value for adherence indicators, of which only 18.8% of pharmacies complied with the above 75% cut-off point. However, adherence to all domains of GPP assessed was below 25%.



Similarly, in a study done by Wijesinghe et al., 2007, cut off value of 80% had been set and there were deficiencies in registration, the pharmacy premises, order of pharmacy, storage of drugs, maintenance of the cold chain, dispensing and documentation. The GPP adherence reported from hospital pharmacy and health facility was 56.67%[23] and 57%[37] respectively.

Although three studies in system domain have relatively low adherence rate; 18.65%[36], 29.6%[24], 39.04%[30], Cristuta et al., 2024,

reported the highest (96.2%) score in system as well as premises/facilities, storage, and dispensing.

3.5. Domain specific GPP adherence rates

The GPP adherence range to different domains reported in the articles are as follows [Table 2]; premises/facilities (n=9)(47.8%[26] - 94.7%[15]), storage (n=12)(36%[26] - 75.4%[27])system (n=5) (18.65%[36] - 75.4%[27]), services and health promotion (n=10) (21.6%[30]- 86.10%

Table 1. Summary of included studies

Study details Country	Study pop /Sample size	GPP domains	V	R	Questionnaire used
(Wijesinghe et al., 2007) [16] Srilanka	CP/38	Registration of the pharmacy, physical environment, order of the pharmacy, storage of drugs, maintenance of the cold chain, dispensing and documentation	Yes	No	Country Checklist. The items were based on requirements of the Drugs Act and relevant aspects of GPP found in publications.
(Tiyyagura et al., 2014) [36] India	CP/100	System, storage, services, dispensing, rational use of drug	No	No	Trap et al., 2010 indicator tool
(Poudel et al., 2016) [26] Nepal	CP and wholesale/ 100	Physical premises only: Cleanliness, ventilation, protection from physical	Yes	Yes	Self-developed based on provisions on drug act and



		environment, spaciousness, storage facilities			code on sale and distribution of drug
(Trap <i>et al.</i> , 2016) [37] Uganda	Health Facility Pharmacy /455	Revisions were based on international GPP standards, the WHO rational drug use indicators, and SPARS indicators, 79 GPP indicators.	Piloting done.	Piloting done but reliability data is not available	Trap <i>et al.</i> , 2010 Revised tool
(Gyawali <i>et al.</i> , 2017) [30] Nepal	CP/150	System Indicator: prescription recording system, use of a computer, use of inventory control system; Storage Indicator: storage conditions, pharmacy hygiene, an arrangement of medicines in pharmacy; Service Indicator: personnel qualifications, working hours of personnel, additional tests provided by the pharmacy.	No	No	Self-developed
(Lama <i>et al.</i> , 2017) [24] Nepal	CP/64	System, storage, services, dispensing, rational use of drug	No	No	Trap <i>et al.</i> indicator tool
(Sapkota <i>et al.</i> , 2024) [34] Nepal	CP/85	Premises, personnel, quality policy, storage, services, documentation, procurement, dispensing and prescription handling	Yes	Cronbach alpha - 0.7	Self-developed
(Gainju <i>et al.</i> , 2019) [23] Nepal	Hospital Pharmacy/64	System, storage, services, dispensing, rational use of drug	No	No	Trap <i>et al.</i> , 2010 indicator tool

(Acharya & Khanal., 2020) [31] Nepal	CP/94	premises, personnel, quality policy, service strategy, documentation, procurement, storage, prescription handling and dispensing system	No	Reliability only. Cronbach's alpha - 0.938	Self-designed closed ended questionnaire
(Badro <i>et al.</i> , 2020) [29] Lebanon	CP/211	A-Data management and data recording, B-services and health promotion, C-dispensing, prep and admins, D- Storage and facilities	No	Reliability only. Cronbach alpha A- 0.833, B- 0.301, C- 0.119 and D- 0.526	Self-designed based on Trap <i>et al.</i> , 2010, 109 item questionnaire.
(Sombatp oothon <i>et al.</i> , 2022) [35] Thailand	CP/280	management for qualities, good pharmaceutical services, Compliance and ethics, service provision and social participation	No	Reliability only. Cronbach alpha = 0.86	Country checklist. Questionnaire based on GPP tool developed by Order Pharmacist in Lebanon (OPL)
(Punturungsee & Ploylearn sang., 2023b) [30] Thailand	CP/32	5 categories of GPP including 1) 9-item of Place requirements; 2) 6-item of Equipment for sale, store, and control or preserve the quality of drugs; 3) 5-item of personnel in pharmacy development; 4) 7-item of Quality control for medication; and 5) 12-item of Pharmacy service or practice in pharmacy.	No	No	Country checklist. 39-item standard assessment according to the Food and Drug Administration, Ministry of Public Health.

(Bou-Saba <i>et al.</i> , 2023)[5] Lebanon	CP/250	Total 3: Indicator B (Services and facilities) Indicator C (Dispensing) Indicator D (Storage)	No	Cronbach alpha= 0.615	Country checklist. Questionnaire based on GPP tool developed by Order Pharmacist in Lebanon (OPL)
(Cristuta <i>et al.</i> , 2024) [27] Philippines	CP/321	data management and data recording services and facilities, dispensing, preparation, administration and distribution of medicines, storage	Yes	Reliability= 0.813	Questionnaire based on Badro et al, 2020
(Vongsavath <i>et al.</i> , 2025)[28] Lao PDR	CP/180	The checklist consisted of facility, storage, services, dispensing and rational use.	No	No	Food and Drug Department (FDD) developed checklist
(Punturongsee & Ploylearnsang., 2023a) ³¹ Thailand	CP/62	5 categories of GPP including 1) 9-item of Place requirements; 2) 6- item of Equipment for sale, store, and control or preserve the quality of drugs; 3) 5-item of personnel in pharmacy development; 4) 7-item of Quality control for medication; and 5) 12- item of Pharmacy service or practice in pharmacy.	No	No	Country checklist. 39-item standard assessment according to the Food and Drug Administration, Ministry of Public Health.
Shrestha & Ghale., 2018) [25] Nepal	CP/64	System, storage, services, dispensing, rational use of drug	No	Kuder Richardson 20 coefficient = 0.769.	Self-developed

CP- Community Pharmacy

V – Validation

R- Reliability

[15]), dispensing(n=9)(28%[31] - 68.61%[27]), and rational use of medicine (n=4)(36%[36] - 52.76% [28]). Cristuta et al.,2025 reported the highest adherence rate to premises/facilities,



storage, system, and dispensing. Six of the nine studies that assessed adherence to premises domain had score above 60% while six of the twelve in storage domain.

3.6. Discussion

The adherence to GPP reported in the included studies ranged from 43.20%[24] to 89%[35] with

less than 70% adherence rate in majority of the studies [23,24,28,31–34,36,37]. The most assessed GPP domains were storage (n=10) followed by services and health promotion (n=9) and dispensing (n=8). Since the main purpose of GPP is to provide optimal, evidence-based care and promote the medication

Table 2. Summary of sample size and GPP domain specific adherence rate

Study Site		Compliance rate to GPP domains (%)						
		Over all GPP (n=16)	P/F (n=9)	Storage (n=12)	Services (n=11)	RUD (n=4)	Dispensing (n=9)	System (n=5)
[16]	CP/38	45.1	65.55	34.14	NA	NA	21	NA
[36]	CP/100	45.48	NA	71.74	35	NA	59.1	18.65
[26]	CP and W/ 100	NA	47.8	36	NA	NA	NA	NA
[37]	HF/455	57	NA	NA	NA	NA	NA	NA
[30]	CP/150	59.3	NA	66.85	57.28	NA	NA	39.04
[24]	CP/64	43.2	NA	51.42	54.16	44.6	37.35	29.6
[34]	CP/85	56.21	57	46.75	47	NA	53.5	NA
[23]	HP/64	56.67	NA	66.13	55.41	52.4	51.27	51.74
[31]	CP/94	50.84	64.4	52.5	36	NA	28	NA
[29]	CP/211	18% pharmacies >75% To GPP						
[35]	CP/280	89	NA	NA	NA	NA	NA	NA

[33]	CP/62	65.71	85	NA	57.34	NA	NA	NA
[15]	CP/250	65.09	NA	66.31	56.91	NA	68.61	NA
[27]	CP/321	84	94	75.4	NA	NA	NA	96.2
[27]	CP/180	60.48	80.34	61.68	57.88	52.8	63.33	NA
[32]	CP/32	65.71	86.30	NA	56.17	NA	NA	NA
[25]	CP/	53.52	58.86	46	53.73	52.41	53.13	NA

NA - not available CP - Community Pharmacy W
- Wholesale HP-Hospital Pharmacy

HF- Health Facility RUD -Rational Use of Drug
P-Premises S-Storage

Since the main purpose of GPP is to provide optimal, evidence-based care and promote the medication safety, there is no any room for compromise. The desirable patient outcome is not achievable with current GPP adherence in developing countries as a consequence it can compromise patient safety, reduce effectiveness of pharmacy services, increase drug resistance. High-income countries have already shifted their focus towards patient oriented pharmacy care [3] but developing countries whose focus is in manufacturing and dispensing medicines still have adherence rate as low as 36%[26] and 28%[31] in storage and dispensing domains respectively.

Few studies included in this review have identified following reasons for such low GPP adherence rates; time restrictions, lack of understanding of GPP, lack of training and resources, time constraints, excessive workload, workforce

shortage, lack of support from employers and other colleagues [27], non-trained health staff [31] and non-licensees [30] (Poudel & Ishii, 2016), guideline not tailored to context [29], inadequate budget, lack of support from other organizations or agencies, workload problems, Public relations problem [32].

Out of the six GPP- Pilot project (2005-2007)[2] countries viz; Thailand, Vietnam, Uruguay, Paraguay, Moldova and Mongolia, there were studies only in Thailand and Vietnam. Sombatpoothon *et al.*, 2020 although, didn't directly report overall GPP adherence rate, it was calculated from the available data on GPP domains and in doing so, in this study and other, the data available for reported domain is considered as 100% for calculation.

FIP states that each country should develop GPP guidelines as per their needs, considering the situation and available resources [2]. Thus, the use of a checklist based on the GPP guidelines of individual countries can act as a gold standard for assessing GPP for that particular country. However, we cannot easily obtain a comparable



adherence rate with such tools, and to address this problem, indicator tool for assessing GPP [14] seems convincing although, its wide use was not found. Such tools save a lot of time pertaining to the smaller number of variables to be assessed. But the benefits of having a single gold standard data collection instrument are immense, as it picturizes the GPP scenario worldwide. It has been more than a decade, but the limitation of Trap *et al.*, 2010, i.e. lack of patient care component, raised in the study has not been addressed by new researchers yet. Most studies included in this review have concentrated on the assessment towards the first role of Pharmacists [13] i.e. to prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products dictated by FIP GPP guideline.

3.7. Limitations of study

Since a common tool for data collection was not used in included studies, the overall adherence rate from them may not impart the similar meaning. Thus, when referring to the adherence rate individual GPP domain scores need to be referred. Reported adherence of only few domains makes the study compromised in terms of findings and relevance. This limitation can be addressed by conducting more adherence studies through the development of domain specific standardized GPP assessment tool, utilizing the protocol mentioned for validation of community pharmacy services [38]. Potential biases in this study includes exclusion of non-English studies, reliance on secondary data, and the lack of a standardized tool for assessing GPP adherence.

4. CONCLUSION

As the quality care standards like Good Pharmacy practice assures the effectiveness of the pharmacy services, pharmacy professionals, decision makers and implementation facilitators from developing

countries need to focus on promoting GPP adherence. In order to achieve this among many barriers to GPP implementation attention to the contextual factors like unstrict regulation, lack of awareness and concept and strong commitment towards implementation needs to be given. And to assure the GPP assessment's reflectability to the real practice and relatability among countries it is necessary GPP philosophy to develop domain specific standardized GPP assessment tool with adaptability potential in diverse pharmacy settings although it is challenging due to diverse country-specific regulations, resources, and healthcare systems.

Acknowledgement

The authors are thankful to all the Department of Pharmacies of Universities of Nepal for providing the information on the grey literatures related to the study. The authors would like to thank the developer of Prisma flow diagram generator[39].

Conflict of Interest

"None to declare"

Statement of Contribution of Researchers

(Concept – B. K.C., A.R.P.; Design – B.K.C., A.R.P.; Supervision – U.B., N.S.; Resources – U.B., N.S.; Materials – U.B., N.S.; Data Collection and/or Processing – B.K.C., U.B., N.S., A.R.P., R.K.S., S.S., N.M., A.T., S.K.C.; Analysis and/or Interpretation – B. K.C., A.R.P., S.S., N.M., S.K.C.; Literature Search – B.K.C., A.T.; Writing – B.K.C., R.K.S., S.K.C., S.S.; Critical Reviews – R.K.S., S.S., N.M., A.T.).

REFERENCES

1. Wiedenmayer, Karin, Summers, Rob S., Mackie, Clare A., Gous, Andries G. S., Everard, Marthe et al. Developing pharmacy



- practice: a focus on patient care: handbook, 2006 edition. World Health Organization and International Pharmaceutical Federation. [Cited 2026 January 05]. Available from: <https://iris.who.int/handle/10665/69399>
2. International Pharmaceutical Federation. Good Pharmacy Practice (GPP) in developing: Recommendations for step-wise implementation. Hague ;1997. [Cited 2025 December 23]. Available from: <https://www.fip.org/files/fip/Statements/GPP%20recommendations.pdf>
3. Al-Worafi, Y.M. (2024). Pharmacy Practice: Comparison Between the Developing Countries. Handbook of Medical and Health Sciences in Developing Countries. Springer, Cham.p.1-55. 2024. https://doi.org/10.1007/978-3-030-74786-2_500-1
4. Babar Z-U-D, Scahill S. Barriers to effective pharmacy practice in low- and middle-income countries. *Integr Pharm Res Pract* 2014;3:25–7. <https://doi.org/10.2147/IPRP.S35379>
5. Pharmacy Council of India. (2015). Pharmacy Practice regulation of India. New Delhi, India. [Cited 2026 January 05]. Available from:<https://thc.nic.in/Central%20Governmental%20Regulations/Pharmacy%20Practice%20Regulations%202015.pdf>
6. Indian Pharmaceutical Association. (2002). Good Pharmacy Practice guideline. Guidelines for delivery of pharmaceutical services and care in Community Pharmacy Settings in India. Mumbai, India. [Cited 2026 January 05]. Available from:<https://ipapharma.org/wp-content/uploads/2019/02/gpp-manua-1.pdf>
7. The South African Pharmacy Council. (2004). South Africa. Good Pharmacy Practice Manual. Pretoria, South Africa. [Cited 2026 January 05]. Available from:<https://pharmcouncil.co.za/Media/Default/Documents/Rules%20published%20in%20terms%20of%20section%2035A%20of%20the%20Pharmacy%20Act%2053%20of%201974.pdf>
8. National Medicine Regulatory Authority. (2021). Good Pharmacy Practice guideline. Colombo, Srilanka. [Cited 2026 January 05]. Available from: https://cdn.prod.website-files.com/666d0695ca3ba7fa496a5068/66bb3215fb62323fd0159f5e_GL-014-Good_Pharmacy_Practice_GPP_Guidelineen gy_2_1_1_2.pdf
9. PRC Board of Pharmacy Resolution No. 03, s. 2015 (Philippines). Reinforcing the legal requirement on the mandatory registration of detailmen / medical representatives/professional sales representatives with the professional regulation commission and the professional regulatory board of pharmacy - Supreme Court E-Library[Internet]. [Cited 2026 January 05]. Available from: <https://elibrary.judiciary.gov.ph/thebookshelf/showdocs/10/71183>
10. Thatjuta Wuttiapanich and Tanattha Kitisopee. Economic impact assessment on good pharmacy practice regulation in community pharmacy. *The Thai Journal of Pharmaceutical Sciences* 39 (3), July-September 2015: 110-118.
11. Nepal Pharmacy Council. (2005). National Good Pharmacy Practice guideline. Kathmandu, Nepal. [Cited 2026 January 05]. Available from: <https://nepalpharmacycouncil.org.np/storage/publication/c794d265-2481-48a6-874a9a254e0a6c4e.pdf>
12. Code on sales and distribution of drug 2024 (Nepal). [Cited 2026 February 23]. Available from:<https://dda.gov.np/content/194/drug-sale-and-distribution-code---2080/>
13. International Pharmaceutical Federation. (2011). Good Pharmacy Practice- Joint FIP/WHO guideline on GPP: Standard on quality



- of Pharmacy service[Internet]. [Cited 2026 January 05]. Available from: https://www.fip.org/files/fip/WHO/GPP%20guidelines%20FIP%20publication_final.pdf
14. Trap B, Hansen EH, Trap R, Kahsay A, Simoyi T, Oteba MO, Remedios V, Everard M. A new indicator based tool for assessing and reporting on good pharmacy practice. *Southern Med Review* (2010) 3; 2:4-11
15. Bou-Saba A, Kassak KM, Salameh P. Adherence to Good Pharmacy Practices by Community Pharmacies in Lebanon and Opportunities for Quality Improvement: It is Time to Act. *Integr Pharm Res Pract* 2023;12:25–35. <https://doi.org/10.2147/IPRP.S377635>
16. Wijesinghe PR, Jayakody RL, De A Seneviratne R. An assessment of the compliance with good pharmacy practice in an urban and rural district in Sri Lanka. *Pharmacoepidemiol Drug Saf* 2007;16:197–206. <https://doi.org/10.1002/pds.1277>
17. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | EQUATOR Network[Internet]. [Cited 2026 February 19]. Available from: <https://www.equator-network.org/reporting-guidelines/prisma/>
18. Centre for Reviews and Dissemination. (2026). Adherence of developing countries to Good Pharmacy Practice; A systematic review[Internet]. [Cited 2026 January 05]. Available from: <https://www.crd.york.ac.uk/PROSPERO/view/CRD42024552596>
19. Australian Government Department of Foreign Affairs and Trade. (2022). List of developing countries as declared by the Minister for Foreign Affairs. [Cited 2026 February 19]. Available from: <https://www.dfat.gov.au/about-us/publications/list-of-developing-countries-as-declared-by-the-minister-for-foreign-affairs>
20. NewCastle-Ottawa quality assessment tool- Adapted for cross-sectional studies[Internet] [cited 2026 February 03]. Available from: https://cdn-links.lww.com/permalink/ejgh/a/ejgh_31_9_2_019_07_18_nguyen_15743_sdc1.pdf
21. Gualdi-Russo E, Zaccagni L. The Newcastle–Ottawa Scale for Assessing the Quality of Studies in Systematic Reviews. *Publications* 2026;14:4. <https://doi.org/10.3390/publications14010004>
22. Pathak N, Shrestha P, Dhungana S, Shrestha S. Assessing Adherence to Good Pharmacy Practices in a Provincial Hospital in Nepal: A Quality Improvement Perspective. *Inq J Med Care Organ Provis Financ* 2025;62. <https://doi.org/10.1177/00469580251385399>
23. Gainju SN, K C, Badri, Shrestha, Sweta. Assessment of good pharmacy practice in selected hospital pharmacies of Kathmandu Valley. Kathmandu University, 2019.
24. lama V, K C, Badri, Shrestha, Sweta. Assessment of good pharmacy practice in selected community pharmacy of Kathmandu valley. Kathmandu University, 2017.
25. Shrestha R, Ghale A. Study of good pharmacy practice in community pharmacy of three districts of Kathmandu valley, Nepal. *Int J Sci Rep* 2018;4:240–5.
26. Poudel BK, Ishii I. Assessment of physical premises of selected pharmacies of Nepal. *SAGE Open Med* 2016;4:2050312116654590. <https://doi.org/10.1177/2050312116654590>
27. Cristuta SMN, Cesar JHA. Adherence towards good pharmacy practice of community pharmacists in central Visayas, Philippines. *Int J Pharm Pract* 2024;32:ii51–2.
28. Vongsavath S, Nishino K, Duangdany D, Keohavong B, Inthaphatha S, Yamamoto E. Good pharmacy practice in community



- pharmacies in the Lao People's Democratic Republic: a cross-sectional study. *Int J Pharm Pract* 2025;33:613–20. <https://doi.org/10.1093/ijpp/riaf064>
29. Badro DA, Sacre H, Hallit S, Amhaz A, Salameh P. Good pharmacy practice assessment among community pharmacies in Lebanon. *Pharm Pract* 2020;18:1745. <https://doi.org/10.18549/PharmPract.2020.1.1745>
30. Gyawali M, Baharadar M, Thapa HS, Subedi S, Bhattarai A, Dangi NB. Assessment of Compliance to Good Pharmacy Practice by Community Pharmacies of Bhaktapur and Lalitpur Districts, Nepal 2019.
31. Acharya A and Khanal DP. 2020. Compliance-on-good-pharmacy-practice-gpp-guideline-in-community-pharmacy-of-western-nepal-nepalgunj 2023. *J Pharma Prac Edu* Vol.3 No.2:25.
32. Punturungsee P, Ploylearmsang C. Pharmacy licensees and their characters that affect Good Pharmacy Practice (GPP) Compliance. *Pharm Pract Granada* 2023;21:15.
33. Punturungsee P, Ploylearmsang C. Empowerment interventions for pharmacies to comply with the Good Pharmacy Practice (GPP) in Thailand. *Pharm Pract* 2023;21:1–8. <https://doi.org/10.18549/PharmPract.2023.3.2852>
34. Sapkota B, Pandey B, Karki A, Malla A. Assessing the Indicators of Good Pharmacy Practice in Community Pharmacies: A Cross-Sectional Study. *Inq J Med Care Organ Provis Financ* 2024;61:00469580241273254. <https://doi.org/10.1177/00469580241273254>
35. Sombatpoonthon and, Assadang Polnok*. Factors Associated with Compliance with the Good Pharmacy Practice Criteria among the Certified Quality Community Pharmacies in Chonburi Province, Thailand 2022.
36. Tiyyagura SR, Purnanand A, Rathinavelu MR. Assessment of good pharmacy practice (GPP) in pharmacies of community settings in India. *IOSR J Pharm* 2014;4:27–33.
37. Trap B, Kikule K, Vialle-Valentin C, Musoke R, Lajul GO, Hoppenworth K, et al. First regulatory inspections measuring adherence to Good Pharmacy Practices in the public sector in Uganda: a cross-sectional comparison of performance between supervised and unsupervised facilities. *J Pharm Policy Pract* 2016;9:18. <https://doi.org/10.1186/s40545-016-0068-4>
38. Scicluna CA, Azzopardi LM, Serracino-Inglott A. Validation Instruments for Community Pharmacy. Lap Lambert Academic Publishing GmbH KG; 2012.
39. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020 - compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev* 2022;18:e1230. <https://doi.org/10.1002/cl2.1230>.

HOW TO CITE: Badri K.C., Uttam Budhathoki, Naeti Suksomboon, Asta Ratna Prajapati, Rojeena Koju Srestha, Sweta Shrestha, Nayan Manandhar, Achyut Bikram Thapa, Santosh K.C., Adherence Of Developing Countries To Good Pharmacy Practice: A Systematic Review, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 8, 3669-3683. <https://doi.org/10.5281/zenodo.22060676>

